北京佰仁医疗科技股份有限公司 第三届董事会第十次会议决议公告

Group 1 - The company held its 10th meeting of the 3rd Board of Directors on June 13, 2025, with all 9 directors present, and the meeting was deemed legally valid [2][3][4] - The Board approved the adjustment of the grant price for the 2020 Restricted Stock Incentive Plan from 15.91 yuan/share to 15.11 yuan/share [3][6] - The meeting also approved the cancellation of 7,115.8 shares of unvested restricted stock due to two participants leaving the company [7][8][26] Group 2 - The Board confirmed that the conditions for the 5th vesting period of the initial grant of the 2020 Restricted Stock Incentive Plan were met, allowing for the vesting of 267,772 shares [12][14][37] - The Board also approved the vesting of 18,527 shares from the reserved grant portion for the 3rd vesting period [10][12][30] - The total number of shares to be vested from both the initial and reserved portions is 26,777.2 shares and 18,527 shares respectively [37][30] Group 3 - The company achieved a revenue of 501.8791 million yuan in 2024, meeting the target value, while the net profit was 162.5394 million yuan, reaching 82.09% of the target [26][27] - For the reserved grant portion, the company reported a revenue of 370.6383 million yuan in 2023, achieving 88.25% of the target [29][30] - The company’s stock incentive plan covers 10.74% of the total share capital, ensuring alignment of interests between core employees and the company [37][38]